Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
The Lancet Oncology has recently published the overall survival (OS) data from a head-to-head Phase III clinical trial. The study evaluated a lung cancer treatment as a potential option for patients with advanced squamous cell carcinoma (SCC) of the lung. Click Here to review the study findings.
